ERBB2 and breast carcinoma: Several new studies have shown that growth factor receptor-mediated signal transduction, such as the HER2/phosphoinositide-3-kinases(PI3K)/Akt signaling pathway, has been implicated in conferring resistance to conventional chemotherapy against breast cancer [5,6,7,8].